Maresin 1 mitigates LPS-induced acute lung injury in mice

British Journal of Pharmacology

Volumn 171, Issue 14, 2014, Pages 3539-3550

  Gong, Jie ^a   Wu, Zhou Yang ^a   Qi, Hong ^a   Chen, Lin ^a   Li, Hong Bin ^a   Li, Bo ^a   Yao, Cheng Ye ^a   Wang, Ya Xin ^a   Wu, Jing ^a   Yuan, Shi Ying ^a   Yao, Shang Long ^a   Shang, You ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

acute lung injury; lipopolysaccharide; Maresin 1; neutrophils; platelets; resolution

Indexed keywords

ANTIINFLAMMATORY AGENT; CD24 ANTIGEN; CYTOKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1GAMMA; MARESIN 1; MONOCYTE CHEMOTACTIC PROTEIN 5; MYELOPEROXIDASE; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 7,14-DIHYDROXYDOCOSA-4,8,10,12,16,19-HEXAENOIC ACID; AUTACOID; DOCOSAHEXAENOIC ACID;

ACUTE LUNG INJURY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL GAS; ARTICLE; CELL ADHESION; CELL INFILTRATION; CELL INTERACTION; CONTROLLED STUDY; DOWN REGULATION; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LEUKOCYTE COUNT; LOW DRUG DOSE; LUNG EDEMA; LUNG LAVAGE; LUNG PARENCHYMA; MALE; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; THROMBOCYTE; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY;

ACUTE LUNG INJURY; ADMINISTRATION, INHALATION; ANIMALS; CELL ADHESION; DOCOSAHEXAENOIC ACIDS; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; NEUTROPHILS;

EID: 84903132801     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12714     Document Type: Article

References (52)

1. Abraham E, (2003). Neutrophils and acute lung injury. Crit Care Med 31: S195-S199.
2. Alessandri AL, Sousa LP, Lucas CD, Rossi AG, Pinho V, Teixeira MM, (2013). Resolution of inflammation: mechanisms and opportunity for drug development. Pharmacol Ther 139: 189-212.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
4. Borgeson E, Lonn J, Bergstrom I, Brodin VP, Ramstrom S, Nayeri F, et al. (2011). Lipoxin A(4) inhibits Porphyromonas gingivalis-induced aggregation and reactive oxygen species production by modulating neutrophil-platelet interaction and CD11b expression. Infect Immun 79: 1489-1497.
5. Chatterjee A, Dimitropoulou C, Drakopanayiotakis F, Antonova G, Snead C, Cannon J, et al. (2007). Heat shock protein 90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in murine sepsis. Am J Respir Crit Care Med 176: 667-675.
6. Chiang N, Arita M, Serhan CN, (2005). Anti-inflammatory circuitry: lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot Essent Fatty Acids 73: 163-177.
7. Dalli J, Zhu M, Vlasenko NA, Deng B, Haeggstrom JZ, Petasis NA, et al. (2013). The novel 13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J 27: 2573-2583.
8. Decker Y, McBean G, Godson C, (2009). Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells. Am J Physiol Cell Physiol 296: C1420-C1427.
9. Diamond MS, Staunton DE, de Fougerolles AR, Stacker SA, Garcia-Aguilar J, Hibbs ML, et al. (1990). ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J Cell Biol 111: 3129-3139.
10. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, et al. (2004). Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350: 29-37.
11. Eickmeier O, Seki H, Haworth O, Hilberath JN, Gao F, Uddin M, et al. (2013). Aspirin-triggered resolvin D1 reduces mucosal inflammation and promotes resolution in a murine model of acute lung injury. Mucosal Immunol 6: 256-266.
12. Frenette PS, Moyna C, Hartwell DW, Lowe JB, Hynes RO, Wagner DD, (1998). Platelet-endothelial interactions in inflamed mesenteric venules. Blood 91: 1318-1324.
13. Gong J, Guo S, Li HB, Yuan SY, Shang Y, Yao SL, (2012). BML-111, a lipoxin receptor agonist, protects haemorrhagic shock-induced acute lung injury in rats. Resuscitation 83: 907-912.
14. Grutz G, (2005). New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol 77: 3-15.
15. Jin SW, Zhang L, Lian QQ, Liu D, Wu P, Yao SL, et al. (2007). Posttreatment with aspirin-triggered lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1. Anesth Analg 104: 369-377.
16. Keane MP, Strieter RM, (2002). The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease. Respir Res 3: 5.
17. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
18. Kumasaka T, Quinlan WM, Doyle NA, Condon TP, Sligh J, Takei F, et al. (1996). Role of the intercellular adhesion molecule-1 (ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice. J Clin Invest 97: 2362-2369.
19. Lawrence T, Willoughby DA, Gilroy DW, (2002). Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2: 787-795.
20. Li HB, Wang GZ, Gong J, Wu ZY, Guo S, Li B, et al. (2013). BML-111 attenuates hemorrhagic shock-induced acute lung injury through inhibiting activation of mitogen-activated protein kinase pathway in rats. J Surg Res 183: 710-719.
21. Li H, Wu Z, Feng D, Gong J, Yao C, Wang Y, et al. (2014). BML-111, a lipoxin receptor agonist, attenuates ventilator-induced lung injury in rats. Shock 41: 311-316.
22. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA, (2009). Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 119: 3450-3461.
23. Maderna P, Godson C, (2009). Lipoxins: resolutionary road. Br J Pharmacol 158: 947-959.
24. Marcon R, Bento AF, Dutra RC, Bicca MA, Leite DF, Calixto JB, (2013). Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis. J Immunol 191: 4288-4298.
25. Matthay MA, Zimmerman GA, (2005). Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol 33: 319-327.
26. Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B, Doerschuk CM, et al. (2003). Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 167: 1027-1035.
27. Matthay MA, Ware LB, Zimmerman GA, (2012). The acute respiratory distress syndrome. J Clin Invest 122: 2731-2740.
28. Matute-Bello G, Downey G, Moore BB, Groshong SD, Matthay MA, Slutsky AS, et al. (2011). An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol 44: 725-738.
29. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
30. Moon C, Han JR, Park HJ, Hah JS, Kang JL, (2009). Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res 10: 18.
31. Nordgren TM, Heires AJ, Wyatt TA, Poole JA, Levan TD, Cerutis DR, et al. (2013). Maresin-1 reduces the pro-inflammatory response of bronchial epithelial cells to organic dust. Respir Res 14: 51.
32. Ortega-Gomez A, Perretti M, Soehnlein O, (2013). Resolution of inflammation: an integrated view. EMBO Mol Med 5: 661-674.
33. Patel BV, Wilson MR, Takata M, (2012). Resolution of acute lung injury and inflammation: a translational mouse model. Eur Respir J 39: 1162-1170.
34. Phillipson M, Heit B, Colarusso P, Liu L, Ballantyne CM, Kubes P, (2006). Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J Exp Med 203: 2569-2575.
35. Ranieri VM, Suter PM, Tortorella C, De Tullio R, Dayer JM, Brienza A, et al. (1999). Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA 282: 54-61.
36. Sakamoto S, Okanoue T, Itoh Y, Sakamoto K, Nishioji K, Nakagawa Y, et al. (1997). Intercellular adhesion molecule-1 and CD18 are involved in neutrophil adhesion and its cytotoxicity to cultured sinusoidal endothelial cells in rats. Hepatology 26: 658-663.
37. Seki H, Fukunaga K, Arita M, Arai H, Nakanishi H, Taguchi R, et al. (2010). The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J Immunol 184: 836-843.
38. Serhan CN, (2007). Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 25: 101-137.
39. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, et al. (2002). Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 196: 1025-1037.
40. Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, et al. (2009). Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 206: 15-23.
41. Serhan CN, Dalli J, Karamnov S, Choi A, Park CK, Xu ZZ, et al. (2012). Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J 26: 1755-1765.
42. Shang Y, Yao S, (2014). Pro-resolution of inflammation: a potential strategy for treatment of acute lung injury/acute respiratory distress syndrome. Chin Med J (Engl) 127: 801-802.
43. Shang Y, Jiang YX, Xu SP, Wu Y, Wu ZY, Yuan SY, et al. (2009). Reduction of pulmonary inflammatory response by erythropoietin in a rat model of endotoxaemia. Chin Med J (Engl) 122: 834-838.
44. Shang Y, Jiang YX, Ding ZJ, Shen AL, Xu SP, Yuan SY, et al. (2010). Valproic acid attenuates the multiple-organ dysfunction in a rat model of septic shock. Chin Med J (Engl) 123: 2682-2687.
45. Uhlig S, Uhlig U, (2004). Pharmacological interventions in ventilator-induced lung injury. Trends Pharmacol Sci 25: 592-600.
46. Wang B, Gong X, Wan JY, Zhang L, Zhang Z, Li HZ, et al. (2011). Resolvin D1 protects mice from LPS-induced acute lung injury. Pulm Pharmacol Ther 24: 434-441.
47. Wheeler AP, Bernard GR, (2007). Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 369: 1553-1564.
48. Xie W, Wang H, Wang L, Yao C, Yuan R, Wu Q, (2013). Resolvin D1 reduces deterioration of tight junction proteins by upregulating HO-1 in LPS-induced mice. Lab Invest 93: 991-1000.
49. Xu H, Gonzalo JA, St Pierre Y, Williams IR, Kupper TS, Cotran RS, et al. (1994). Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J Exp Med 180: 95-109.
50. Xu YN, Zhang Z, Ma P, Zhang SH, (2011). Adenovirus-delivered angiopoietin 1 accelerates the resolution of inflammation of acute endotoxic lung injury in mice. Anesth Analg 112: 1403-1410.
51. Zarbock A, Ley K, (2009). The role of platelets in acute lung injury (ALI). Front Biosci (Landmark Ed) 14: 150-158.
52. Zarbock A, Singbartl K, Ley K, (2006). Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 116: 3211-3219.